Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrimeprazine versus haloperidol for cancer-related nausea not caused by anticancer treatment
ACTRN12615000177550Phase 3Completed
- Sponsor
- Palliative Care Clinical Studies Collaborative
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nausea ((none)) comparing Methotrimeprazine arm with Haloperidol arm (2 arms). Primary endpoint: Response to treatment at 72 hours. Started Mar 2015; status: completed.
02
Drugs
levomepromazinehaloperidol
03
Conditions
nausea ((none))
Beyond the preview
Go deeper on ACTRN12615000177550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000177550.